Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842087 | 0.96 | MAPK1 (0.38) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL4849206 | 0.89 | KDM4E (0.30) | MAPK1KDM4E | |
| SCHEMBL4848841 | 0.84 | MAPK1 (0.39) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL4850979 | 0.82 | MAPK1 (0.38) | MAPK1DRD2DRD4HRH4CYP1A2 | |
| SCHEMBL4848443 | 0.80 | MAPK1 (0.39) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL6341181 | 0.79 | MAPK1 (0.36) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL3881168 | 0.79 | MAPK1 (0.38) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL4846600 | 0.79 | MAPK1 (0.41) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL4845574 | 0.74 | MAPK1 (0.41) | MAPK1DRD2DRD4HRH4TP53 | |
| SCHEMBL4841926 | 0.73 | PIM1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | claimed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | claimed |
| EP-1509530-B1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | claimed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | claimed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| US-7435834-B2 | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-14 | — | — | US | disclosed |
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | disclosed |
| EP-1509530-B1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | disclosed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | disclosed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | MAPK1 349/4885DRD2 1673/4885DRD4 2210/4885 |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | DBH, MAOB, BCHE | MAPK1 3036/4885DRD2 55/4885DRD4 137/4885 |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | MAPK1 369/4885DRD2 1739/4885DRD4 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.